Get the Stockscreener App
17.29
2.26%
-0.40
After Hours:
17.45
0.16
+0.93%
Arcutis Biotherapeutics Inc stock is traded at $17.29, with a volume of 1.41M.
It is down -2.26% in the last 24 hours and up +17.30% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$17.69
Open:
$17.63
24h Volume:
1.41M
Relative Volume:
0.81
Market Cap:
$2.07B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-4.4107
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
+0.82%
1M Performance:
+17.30%
6M Performance:
+14.05%
1Y Performance:
+64.35%
1-Day Range:
$16.92
$17.71
1-Week Range:
$16.92
$18.15
52-Week Range:
$8.03
$18.15
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
17.29 | 2.11B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Todd Watanabe Sells 9,625 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
22,082 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Ieq Capital LLC - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 12-Month HighHere's Why - MarketBeat
Arcutis Biotherapeutics CEO Watanabe sells $177k in shares - Investing.com
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $583,860.80 in Stock - MarketBeat
Arcutis Biotherapeutics (ARQT) Surges 31% In Last Quarter - Yahoo Finance
Scientech Research LLC Takes $863,000 Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 17.76 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 17.76 USD - Investing.com India
Sell Signal: What are analysts’ price targets for Arcutis Biotherapeutics Inc.2025 Valuation Update & Long-Term Safe Investment Ideas - Lancaster City Council
Chronic Hand Eczema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeut - Barchart.com
Arcutis Biotherapeutics (ARQT): Is the Stock’s Quiet Rally Signaling an Undervalued Opportunity? - Yahoo Finance
Arcutis Biotherapeutics, Inc. $ARQT Stock Holdings Lessened by Cormorant Asset Management LP - MarketBeat
Will Volume Confirm Reversal in Arcutis Biotherapeutics Inc.July 2025 Opening Moves & Weekly High Conviction Ideas - beatles.ru
Relief Rally in Arcutis Biotherapeutics Inc. Stock — Can It Hold2025 Breakouts & Breakdowns & Weekly Watchlist for Consistent Profits - beatles.ru
Will Arcutis Biotherapeutics Inc. Bounce From 52 Week Low2025 Valuation Update & Capital Protection Trading Alerts - beatles.ru
Arcutis Biotherapeutics Inc.’s Price Action Aligns with Quant Signals2025 Macro Impact & Long-Term Growth Plans - beatles.ru
Chart overlay techniques for tracking Arcutis Biotherapeutics Inc.Weekly Trend Report & Consistent Income Trade Ideas - Newser
Using Ichimoku Cloud for Arcutis Biotherapeutics Inc. technicals2025 Market Trends & Verified Entry Point Signals - Newser
ranking arcutis biotherapeutics inc. among high performing stocks via toolsWatch List & Daily Market Momentum Tracking - Newser
Arcutis Biotherapeutics’ Use of Inducement Grants: Strategic Talent Retention or Market Signal? - AInvest
Is Arcutis Biotherapeutics Inc. a defensive stockJuly 2025 News Drivers & Daily Profit Focused Screening - خودرو بانک
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
What’s the outlook for Arcutis Biotherapeutics Inc.’s sector2025 Retail Activity & Risk Managed Investment Entry Signals - خودرو بانک
35,500 Restricted Stock Units: Arcutis Biotherapeutics Grants Equity Awards to New Immuno-Dermatology Team - Stock Titan
Relative strength of Arcutis Biotherapeutics Inc. in sector analysisDividend Hike & Growth Oriented Trading Recommendations - Newser
Long term hold vs stop loss in Arcutis Biotherapeutics Inc.Quarterly Profit Review & Consistent Profit Trading Strategies - Newser
Ranking Arcutis Biotherapeutics Inc. among high performing stocks via toolsWeekly Volume Report & Weekly Breakout Opportunity Watchlist - Newser
What are the risks of holding Arcutis Biotherapeutics Inc.2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - 강소기업뉴스
Paradigm Biocapital Advisors LP Invests $22.92 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Is Arcutis Biotherapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysis2025 Analyst Calls & Entry Point Strategy Guides - Newser
August's FDA Focus: Approvals and pipeline updates in pediatrics - Contemporary Pediatrics
Why is Arcutis Biotherapeutics Inc. stock going upWeekly Profit Recap & Proven Capital Preservation Methods - خودرو بانک
What’s the beta of Arcutis Biotherapeutics Inc. stockJuly 2025 WrapUp & Capital Efficiency Focused Strategies - خودرو بانک
Arcutis seeks FDA approval for psoriasis cream for young children By Investing.com - Investing.com Australia
Live market analysis of Arcutis Biotherapeutics Inc.July 2025 Action & Technical Pattern Based Buy Signals - Newser
Will Arcutis Biotherapeutics Inc. continue its uptrend2025 Earnings Impact & Technical Analysis for Trade Confirmation - Newser
What are analysts’ price targets for Arcutis Biotherapeutics Inc.2025 Investor Takeaways & Daily Profit Maximizing Tips - خودرو بانک
Detecting support and resistance levels for Arcutis Biotherapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - Newser
Will Arcutis Biotherapeutics Inc. rebound enough to break evenPortfolio Value Summary & Verified Swing Trading Watchlist - Newser
What technical models suggest about Arcutis Biotherapeutics Inc.’s comeback2025 EndofYear Setup & Safe Swing Trade Setups - Newser
Chart based analysis of Arcutis Biotherapeutics Inc. trends2025 Earnings Impact & Capital Protection Trading Alerts - Newser
Will Arcutis Biotherapeutics Inc. bounce back from current supportMarket Volume Report & Free High Accuracy Swing Entry Alerts - Newser
When Can We Expect A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)? - 富途牛牛
Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCPLive
Arcutis submits sNDA for roflumilast cream 0.3% for treatment of psoriasis in children 2-5 years - Contemporary Pediatrics
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Arcutis Seeks Expanded Indication for Zoryve - MarketScreener
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):